This is a working overview of DAC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-07 and is reviewed periodically as new material appears.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Chloroformic acid is a chemical compound with the formula ClCO2H. It is the single acyl-halide derivative of carbonic acid (phosgene is the double acyl-halide derivative). Chloroformic acid is also structurally related to formic acid, in a way that the non-acidic hydrogen of formic acid is replaced by chlorine. Despite the similar name, it is very different from chloroform. It is described as unstable, decomposing into carbon dioxide and hydrogen chloride. Chloroformic acid itself is too unstable to be handled for chemical reactions. However, many esters of this carboxylic acid are stable and these chloroformates are important reagents in organic chemistry. They are used to prepare mixed carboxylic acid anhydrides used in peptide synthesis.
=== Os cordis === In some animals, the fibrous trigone can undergo increasing mineralization with age, leading to the formation of a significant os cordis (heart bone), or two (os cordis sinistrum and os cordis dextrum, the latter being the larger one). The os cordis is thought to serve mechanical functions. In humans, two paired trigones (left and right) are seen in this essential view of anatomy. As a surgical purchase point, the Trigones risk much in AV propagation. It has been known since Classical times in deer and oxen and was thought to have medicinal properties and mystical properties. It is occasionally observed in many other artiodactyls including goats, sheep, giraffes, camels, water buffalo, and antelopes but also in carnivorans such as otters, dogs, cats, and sea lions and in the horse. It has also been discovered in chimpanzees, the first known great ape to have an os cordis; it has subsequently been reported in a human, though its etiology is unknown. Against the opinion of his time, Galen wrote that the os cordis was also found in elephants. While it is unclear if Galen actually observed the bone, it has since been identified in Asian elephants.
== Diagnosis == The disease may be diagnosed based on a clinical examination, which identifies signs and symptoms generally associated with the people who have the condition. Genetic testing for known pathological variants is preferred, by testing of the COL6A1, COL6A2, COL6A3 and COL12A1 genes. In the case of a VUS, testing of dermal fibroblast culture is used for an accurate diagnosis. Additional laboratory tests may be performed before genetic testing, such as creatine kinase (CK) blood test, MRI of the muscles, and electromyography (EMG). Phenotypes of overlap between Ullrich congenital muscular dystrophy (UCMD) and Bethlem can be assumed. In the differential diagnosis of UCMD, even in patients without finger contractures, Bethlem myopathy could be considered.
Sources: en.wikipedia.org
Evidence linking late Miocene global cooling and northern Tibetan Plateau uplift to near-synchronous monsoon intensification and turnover of mammalian communities in Asia approximately 8.7 million years ago is presented by Han et al. (2026). Choudhary et al. (2026) describe new mammalian fossil material from the Tapar locality (Gujarat, India), interpreted as corroborating late Miocene age of mammals from the studied locality and providing evidence of their biogeographical links with mammals from the lower Nagri Formation. Patnaik et al. (2026) determine the mammalian assemblage from the Piram Island (India) to be approximately 8.7 million years old. Fossils of a diverse mammalian assemblage, interpreted as living in a wooded savanna environment shortly before the Messinian salinity crisis, are described from the Ouedhref Formation (Tunisia) by Ksila et al. (2026). A study on the mammalian assemblages from the Miocene Sahabi Formation and Pliocene Qarat Weddah Formation at the As-Sahabi site (Libya), providing evidence of changes of composition of the studied assemblages likely linked to environmental changes resulting from the Messinian salinity crisis, is published by Al Riaydh, Fara & Smith (2026). Evidence from geochemical analyses of teeth of Blancan proboscideans and horses from the Rancho Jorge locality (Sonora, Mexico), indicating that the studied mammals lived in arid environment and had mixed diets based on C3 and C4 plants, is presented by Hernández-Sandoval et al. (2026). Li et al.
The degradation of glycerol by some strains of LAB can yield the compound acrolein. Glycerol is a sweet-tasting polyol present in all wines, but at higher levels in wines that have been infected with Botrytis cinerea. An "active-aldehyde", acrolein can interact with some phenolic compounds in wine to create highly bitter-tasting wines, described as amertume by Pasteur. While at least one strain of O. oeni has been shown to produce acrolein, it is more commonly found in wines that have been infected by strains of Lactobacillus and Pediococcus species such as L. brevis, L. buchneri, and P. parvulus. Acrolein taint has also shown to be more common in wines that have been fermented at high temperatures and/or made from grapes that have been harvested at high Brix levels. Heterofermenting species from the genus Lactobacillus, as well as some wild strains of O. oeni, have the potential to metabolize fructose (one of the main sugars in wine) into the sugar alcohols mannitol and (less commonly) erythritol. These are sweet-tasting compounds can add sweetness to a wine where it is not desired (such as Cabernet Sauvignon). Mannitol taint, described as mannite by Pasteur, in wines is often accompanied by other wine faults, including the presence of excessive levels of acetic acid, diacetyl, lactic acid, and 2-butanol, which can contribute to a "vinegary-estery" aroma. The wine may also have a slimy sheen on the surface.
== Overview == Platelet-mimicking particles, an innovation of drug delivery since the mid-twentieth century, are designed to mimic the functionality of natural platelets, with ongoing research focusing on optimizing their biocompatibility, clot integration, and targeted delivery capabilities. Advances in nanotechnology and molecular engineering have enabled the development of platelet-mimicking drug delivery systems. Current research aims to replicate key platelet functions such as adhesion, aggregation, and clotting to enhance hemostatic responses and targeted therapies. Primary synthetic platelet preparations involve nanoscale polymeric architectures, peptides, or extracellular vesicles to improve biocompatibility and therapeutic efficacy. Current iterations of synthetic platelets - hydrogel-based nanoparticles that mimic the size, mechanics, and shape of natural platelets - have demonstrated efficacy in promoting clotting and wound healing in preclinical studies involving rodents and pigs. Originally designed to improve patient outcomes related to hemostasis, synthetic platelets are now being explored in other therapeutic areas including immune modulation and anticancer treatment. For example, a recent platelet design engineered for anticancer treatment can be freeze-dried and rehydrated when needed, offering a longer shelf life compared to natural platelets, which typically degrade rapidly when stored.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.